RENERVE LIMITED — Capital/Financing Update 2024

Dec 9, 2024

==> picture [595 x 99] intentionally omitted <==

ASX Announcement

10 December 2024

ReNerve Signs Exclusive Partnership with Established Supplier in the Middle East to Further Accelerate International Expansion

Highlights:

• ReNerve Limited has partnered with Union MediScience B.S.C in an exclusive distribution agreement for the sales and marketing of the Company’s primary product, the NervAlign[®] Nerve Cuff, in the Middle East

• The agreement covers five (5) countries across the Middle East: Bahrain, Saudia Arabia, Kuwait, UAE/Dubai and Qatar

• Union MediScience is an established medical device distributor across the region with experience in tissue-based products

• The Global Nerve Repair Biomaterials Market was valued at USD$1.96 billion in 2024 and is projected to grow at a CAGR of 17.8% from 2024 to 2031 to USD$6.19 billion[1]

• ReNerve remains well placed to accelerate its international expansion into the Middle East, along with accelerating its regulatory program in other jurisdictions, including Hong Kong.

ReNerve Limited ( ASX:RNV, “ ReNerve ” or “ the Company ”) is pleased to announce that it has signed an exclusive distribution partnership (“ the Agreement ”) with Union MediScience B.S.C (“ Union MediScience ”) based in Bahrain. The agreement covers five countries across the Middle East: Bahrain, Kuwait, UAE/Dubai, Qatar and Saudi Arabia.

Dr. Julian Chick, Managing Director of ReNerve, commented:

"We are thrilled to execute the Agreement with Union MediScience, an established and reputable distributor in the Middle East, to bring the NervAlign® Nerve Cuff to a market with tremendous growth potential. This partnership underscores our commitment to working with trusted local partners who possess deep regional expertise and established networks, ensuring that we can effectively address the critical need for nerve repair solutions in the region.

This partnership aligns seamlessly with ReNerve's strategic focus on global expansion and targeted market entry. By collaborating with Union MediScience, ReNerve leverages a partner with proven expertise and established connections, facilitating regulatory approvals and accelerating market penetration across the MENA region. Furthermore, this Agreement supports the Company's broader vision of commercializing cutting-edge medical technologies in high-growth markets while addressing significant unmet medical needs.”

1 Source: Global Nerve Repair Biomaterials Market Research Report, 2020-2031

157 Heidelberg Rd, Northcote, VIC 3070

+61 (03) 9482 3940

www.renerve.com.au

Market Opportunity

The Middle East is an opportunity with strong growth as awareness as the importance of nerve repair and replacement increases. Market reports suggest the total MENA market is worth over USD$80M per annum and growing at over 35%[2] . The market also has fewer competitors compared to the larger markets like the US.

About Union MediScience

Established in 1988, Union MediScience is a leading company in the Middle East that represents well-known manufacturers worldwide through the supply of medical equipment, medical goods and medicines. It has been one of the leading suppliers in the Bahrain Market for more than two decades and has built a reputation in the industry for its ability to satisfy customer requirements and supply, install and commission specified products on time.

This announcement has been approved for release by the Company’s Board of Directors.

- ENDS -

For further information and enquiries, please contact:

Dr Julian Chick	Dayna Louca
CEO & Managing Director	Investor & Media Relatons
ReNerve Ltd	Jane Morgan Management
+61 (03) 9482 3940	+61 (0) 409 581 972
info@renerve.com.au	dayna@janemorganmanagement.com.au

About ReNerve Limited

ReNerve Limited (ASX:RNV) is an Australian-based biotechnology company specialising in advanced nerve repair and regeneration solutions. The Company is focused on commercialising cutting-edge medical devices and tissueengineering products that seek to address significant unmet needs in peripheral nerve damage patients – a critical gap in healthcare. ReNerve aims to improve patient outcomes through scientifically backed products that have been developed to enhance the human body's natural healing process, while commercialising cutting-edge, scalable products for the healthcare market. ReNerve wishes to acknowledge AusIndustry’s Accelerating Commercialisation program for its support through many of the activities required to commercialise the NervAlign® Nerve Cuff.

2 Source: Global Nerve Repair Biomaterials Market Research Report, 2020-2031

2 | P a g e